Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals by Sylvia Drazilova, Martin Janicko, Lubomir Skladany, Pavol Kristian, Marian Oltman, Maria Szantova, Dusan Krkoska, Eva Mazuchova, Lubica Piesecka, Veronika Vahalova, Marek Rac, Ivan Schreter, Ladislav Virag, Tomas Koller, Adriana Liptakova, Miriam Ondrasova, Peter Jarcuska

“…Data about glycemia, history of diabetes, hepatitis C virus, treatment, and liver status, including elastography, were obtained at baseline (before treatment start), at the end of treatment and 12 weeks after the end of treatment. …”
Get full text

Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients by Jiayi Wang, Lingyao Du, Dongmei Zhang, Chen Zhou, Yilan Zeng, Miao Liu, Xing Cheng, Xiaona Song, Han Chen, Ning Han, Enqiang Chen, Hong Tang

“…Background: Hepatitis C virus (HCV) eradication with sofosbuvir/velpatasvir (SOF/VEL) represents a significant advancement, offering hope for eliminating the virus in diverse patient populations. …”
Get full text

Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial) by Marina V. Mayevskaya, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda, V. T. Ivashkin

“…Beneficial interferon properties include: absence of mutagenic capacity for hepatitis C virus and drug interaction, stimulation of host immune response. …”
Get full text

Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver disease by Thomas F Baumert, Charlotte Bach, Patrick Pessaux, Catherine Schuster, Frank Jühling, Sarah C Durand, Yujin Hoshida, Fabien Zoulim, Atish Mukherji, Naoto Fujiwara, Marine A Oudot, Armando Andres Roca Suarez, Michel L Tremblay, Barbara Testoni, Joachim Lupberger, Romain Parent, Laurent Mailly, Nassim Dali-Youcef, Emanuele Felli, Maria Saez-Palma, Julien Moehlin, Alessia Virzì, Nicolas Brignon, Eugenie Schaeffer, Romain Martin, Laura Meiss-Heydmann, Zakaria Boulahtouf, Lea Girard, Emma Osswald, Carole Jamey, Daniel Brumaru, Bhuvaneswari Koneru

“…Objective Impaired hepatic expression of protein tyrosine phosphatase delta (PTPRD) is associated with increased STAT3 transcriptional activity and reduced survival from hepatocellular carcinoma in patients with chronic hepatitis C virus infection. However, the PTPRD-expressing hepatic cell types, signalling pathways responsive to PTPRD and their role in non-viral liver disease are largely unknown.Methods We studied PTPRD expression in single-cell and bulk liver transcriptomic data from mice and humans, and established a Ptprd-deficient mouse model for metabolic dysfunction-associated steatohepatitis (MASH). …”
Get full text

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy by Amit Chopra, Creticus Marak, Narendrakumar Alappan, Chang Shim

“…Hepatitis C virus infection is the leading cause of chronic liver disease in the United States of America. …”
Get full text

An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function by Shyam Patel, Jennifer Andres, Kamran Qureshi

“…Hepatitis C virus (HCV) infection affects roughly 170 million people worldwide. …”
Get full text

Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016 by Leisha D. Nolen, Courtney Gustin, Sara Seeman, Neil Murphy, Sarah Truitt, Sarah Schillie, Michael G. Bruce, Dana Bruden, James Tiesinga, Brian McMahon

“…Hepatitis C virus (HCV) infection in pregnant women is of concern as it presents a health threat not only to the mother, but also to her infant. …”
Get full text

Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience) by I. Yu. Pirogova, N. B. Kovaleva, E. P. Patlusov, E. S. Radchenko

“…Overall 164 patients with hepatitis C viruses (HCV) genotypes 1, 2 and 3 in 4 medical centers received antiviral therapy. …”
Get full text